Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031010 | 0.84 | SMN1; SMN2 (0.38) | ALDH1A1MAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL15985647 | 0.83 | ALDH1A1 (0.30) | ALDH1A1MAPTTDP1L3MBTL1POLB | |
| SCHEMBL15354850 | 0.77 | CA12 (0.35) | ALDH1A1MAPTL3MBTL1MEN1NPC1 | |
| SCHEMBL2058683 | 0.70 | MEN1 (0.35) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15452217 | 0.70 | POLM (0.37) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL9637370 | 0.69 | SMN1; SMN2 (0.36) | ALDH1A1MAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL20078883 | 0.67 | MAPT (0.34) | ALDH1A1MAPTTDP1L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL15720562 | 0.66 | SMN1; SMN2 (0.36) | ALDH1A1MAPTL3MBTL1MEN1GAA | |
| SCHEMBL18733490 | 0.65 | TGM2 (0.30) | — | |
| SCHEMBL3267635 | 0.64 | MEN1 (0.41) | ALDH1A1MAPTTDP1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029461-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9017954-B2 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | TYR, TH, TYRO3 | ALDH1A1 1205/4885MAPT 4799/4885TDP1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.